Evidence map›Paper›PMID 31332543›Full record

ArticleMedical oncology (Northwood, London, England)2019

Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series.

John M Kennedy, Xiaoming Wang, Komal R Plouffe, Saravana M Dhanasekaran, Khaled Hafez, Ganesh S Palapattu, Tobias Else, Alon Z Weizer, Todd M Morgan, Daniel E Spratt and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

John M KennedyDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Xiaoming WangMichigan Center for Translational Pathology, Ann Arbor, MI, USA.
Komal R PlouffeDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Saravana M DhanasekaranMichigan Center for Translational Pathology, Ann Arbor, MI, USA.
Khaled HafezDepartment of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
Ganesh S PalapattuDepartment of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
Tobias ElseDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Alon Z WeizerDepartment of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
Todd M MorganDepartment of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
Daniel E SprattDepartment of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.
Matthew S DavenportDepartment of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
Arul M ChinnaiyanDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Aaron M UdagerDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Rohit MehraDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. mrohit@med.umich.edu.ORCID http://orcid.org/0000-0002-6955-8884
University of Michigan · USMichigan Center for Translational Pathology · USHoward Hughes Medical Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary renal cell carcinoma syndromes (HRCCS) are characterized by the presence of pathogenic germline variants that predispose patients to renal cell carcinomas as well as additional extra-renal manifestations. The importance of identifying HRCCS patients cannot be overemphasized, as patients and their families can begin surveillance for syndrome-associated manifestations once identified. The present study is a retrospective clinical and morphologic review of 60 hereditary renal tumors from 30 HRCCS patients treated at our institution with either Von Hippel-Lindau disease (VHL), Birt-Hogg-Dubé syndrome (BHD), tuberous sclerosis complex (TSC), hereditary leiomyomatosis and renal cell cancer syndrome, or succinate dehydrogenase (SDH) deficiency syndrome. Hereditary renal cell carcinoma syndromes kidney tumors often demonstrate specific morphologic features, characteristic background changes in renal parenchyma, and extra-renal manifestations, which, when recognized by the pathologist, can trigger genetic testing referral for specific familial cancer syndromes. Our study demonstrates the majority of tumors were consistent with the anticipated clinicopathologic profile of renal tumors found within HRCCS patients, although we found some unique characteristics within this cohort including a case of clear cell papillary renal cell carcinoma within a VHL patient, and a unique renal tumor with tubulopapillary features present in a patient with a germline SDHD mutation. Additionally, although the literature reports the presence of epithelioid angiomyolipoma (AML) as a common occurrence in TSC patients, our cohort of 3 patients with AMLs demonstrated only classic features. The findings we describe facilitate pathologist-based recognition of HRCCS and can prompt genetic evaluation for relevant patients.

Indexed as

AdolescentAdultAgedBiomarkers, TumorCarcinoma, Renal CellChildFemaleGenetic Diseases, InbornHumansKidneyKidney NeoplasmsMaleMiddle AgedNeoplastic Syndromes, HereditaryParenchymal TissueRetrospective StudiesBiomarkers, TumorSuccinate DehydrogenaseBirt-hogg-dubéHereditary leiomyomatosis and renal cell carcinoma syndromeHereditary renal cell carcinomaSuccinate dehydrogenase deficiencyTuberous sclerosis complexVon hippel-lindau

Identifiers

PMID31332543
OpenAlexW2963526553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.